Glycosylation End Products, Advanced - Antagonists & inhibitors
Research News and Information

Sunday, November 22, 2009

Hepatocyte growth factor prevents advanced glycation end products-induced injury and oxidative stress through a PI3K/Akt-dependent pathway in human endothelial cells.

20 Sep 2009 AIMS: Advanced glycation end products (AGEs) trigger an oxidative reaction which then accelerates endothelial cell apoptosis; this is a critical event in the process of diabetic vascular complications. We previously demonstrated that hepatocyte ... Read more...

[Usefulness of metformin in diabetes-related bone disease]

30 Aug 2009 Accumulative evidence shows that type 2 diabetes patients have high fracture rate in spite of the absence of bone mineral density (BMD) reduction. The etiology and treatment of diabetes-related bone disease have recently attracted widespread ... Read more...

Inhibitors of aldose reductase and formation of advanced glycation end-products in moutan cortex (Paeonia suffruticosa).

30 Jul 2009 The methanol extract of Moutan cortex (Paeonia suffruticosa) afforded two new compounds, 8-O-benzoylpaeonidanin (1) and 5-hydroxy-3S-hydroxymethyl-6-methyl-2,3-dihydrobenzofuran (2), in addition to 4-O-butylpaeoniflorin (3) as an artifact of the ... Read more...

Latest indexed articles for 'Glycosylation End Products, Advanced - Antagonists & inhibitors'

These are the very latest articles for this heading:

• Hepatocyte growth factor prevents advanced glycation end products-induced injury and oxidative stress through a PI3K/Akt-dependent pathway in human endothelial cells. 20 Sep 2009
• [Usefulness of metformin in diabetes-related bone disease] 30 Aug 2009
• Inhibitors of aldose reductase and formation of advanced glycation end-products in moutan cortex (Paeonia suffruticosa). 30 Jul 2009
• Histamine inhibits advanced glycation end products-induced adhesion molecule expression on human monocytes. 28 Jun 2009
• Blockade of advanced glycation end product formation attenuates bleomycin-induced pulmonary fibrosis in rats. 22 Jun 2009
• Reactive immunization suppresses advanced glycation and mitigates diabetic nephropathy. 21 Apr 2009
• Flavan-3-ols having a gamma-lactam from the roots of Actinidia arguta inhibit the formation of advanced glycation end products in vitro. 30 Mar 2009
• N-Terminal 2,3-diaminopropionic acid (Dap) peptides as efficient methylglyoxal scavengers to inhibit advanced glycation endproduct (AGE) formation. 18 Feb 2009
• Recent advances in pharmacotherapy for diabetic nephropathy: current perspectives and future directions. 12 Feb 2009
• Metabolic interactions of AGE inhibitor pyridoxamine and antioxidant alpha-lipoic acid following 22 weeks of treatment in obese Zucker rats. 9 Feb 2009
• Protein glycation inhibitory activities of Lawsonia inermis and its active principles. 30 Jan 2009
• Phase I clinical studies of the advanced glycation end-product (AGE)-breaker TRC4186: safety, tolerability and pharmacokinetics in healthy subjects. 30 Dec 2008
• State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatment and therapeutic management of a group of sight-threatening eye diseases. 30 Dec 2008
• Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy - are these receptors valid therapeutic targets. 30 Dec 2008
• Seasonal phytochemical variation of anti-glycation principles in lowbush blueberry (Vaccinium angustifolium). 13 Dec 2008
• Adverse renal effects of the AGE inhibitor pyridoxamine in combination with ACEi in non-diabetic adriamycin-induced renal damage in rats. 17 Nov 2008
• Diabetic nephropathy: important pathophysiologic mechanisms. 11 Nov 2008
• Flavan-3-ols from Ulmus davidiana var. japonica with inhibitory activity on protein glycation. 5 Nov 2008
• KIOM-79 prevents apoptotic cell death and AGEs accumulation in retinas of diabetic db/db mice. 30 Oct 2008
• Inhibition of advanced glycation end products (AGEs): an implicit goal in clinical medicine for the treatment of diabetic nephropathy? 24 Oct 2008

See a longer list of these articles.

Technical information about 'Glycosylation End Products, Advanced'

Definition: Products derived from the nonenzymatic reaction of glucose and proteins in vivo that exhibit a yellow-brown pigmentation and an ability to participate in protein-protein cross-linking. These substances are involved in biological processes relating to protein turnover and it is believed that their excessive accumulation contributes to the chronic complications of diabetes mellitus.

Registry Number: 0

Descriptor UI: D017127

Alternative terms: Glycosylation End Products, Advanced; Advanced Glycosylation End Products; Glycation End Products, Advanced; Advanced Glycation End Products;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D02.415;

History Note: 93

Technical Notes: DF: GEPA